UNSPSC 51101648: Clefamide

This classification denotes an antiprotozoal agent with the molecular formula C17H16Cl2N2O5, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 4AZ2V8K4EK, chemically known as 2,2-dichloro-n-(2-hydroxyethyl)-n-(p-(p-nitrophenoxy)benzyl)acetamide but generally known as clefamide, which bears US NIH Compound Identifier 71819. European Medicines Agency schedules Clefamide in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06647MIG.

UNSPSC 51101648 Clefamide, a Commodity code, appears in state and local procurement records with minimal recent activity directly aligned to the code's nominal scope. The two most recent opportunities tagged to this code involve pharmaceutical products — one a completed award through Illinois Department of Public Health for Doxycycline Hyclate and Ciprofloxacin Hydrochloride, and one an active solicitation by Seminole County, Florida for Naloxone and drug deactivation systems — neither of which are clefamide products. The code shows little relevant recent activity under its stated commodity classification, suggesting either sparse demand for clefamide in state and local procurement or systematic mislabeling of opportunities in the underlying data.

The geographic spread across the two records spans Illinois and Florida, but both opportunities reflect pharmaceutical procurement more broadly rather than demand specific to clefamide. The Illinois Department of Public Health awarded a $2,999,999.11 piggyback contract through MMCAP Infuse to Chartwell Rx LLC via IFB on August 28, 2026, for antibiotic tablets with an initial 12-month term and two renewal options. Seminole County released an IFB on June 30, 2026, for 1,900 units of Naloxone and 800 Safe Drug Deactivation Systems annually with quarterly deliveries, a two-year initial term plus one-year renewal option, and potential FEMA funding with associated federal compliance requirements. No set-asides or enterprise preferences were identified. Business development professionals evaluating this code should verify whether clefamide procurement activity exists outside these records or whether the code itself requires clarification from state and local procurement offices.